- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04778813
Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2) (CHIMIO2)
Bakground In Burkina Faso, since the adoption of this new malaria treatment policy in 2005, several studies evaluating the efficacy and tolerance of ACTs have been carried out by different research teams at different sites according to an irregular chronology and according to different methods. Studies conducted in children 6 to 59 months with supervised use of ACTs indicate adequate clinical and parasitological response rates varying between 93% to 98% after correction to the PCR at day 28. With the introduction of seasonal malaria chemoprevention (SMC) by the Sulfadoxine-Pyriméthamime/amodiaquine combination in almost all health districts of Burkina Faso, ASAQ is no longer recommended for the treatment of uncomplicated malaria in the areas covered by this intervention. In 2017, DHA-PPQ was added to the national treatment guidelines as a first-line treatment option. The therapeutic efficacy study carried out in 2017-2018 by the CNRFP showed a PCR-corrected treatment failure rate of over 10% with the AL combination. However, molecular analyzes have not shown the presence of mutations at position 580 on the PfK-13 gene which is associated with resistance to artemisinin derivatives. The combination artesunate-pyronaridine (As-Pyr) was recently added to the WHO Prequalified Medicines List and Essential Medicines List. In 2019, it received regulatory marketing authorization to be used as a treatment for malaria in Burkina Faso. Burkina Faso (along with the Niangoloko and Bobo Dioulasso centers) was one of the countries where clinical trials p ar the As-Pyr association were led. This combination has been found to be effective and well tolerated in Burkina Faso. The combinations of AL and DHA-PPQ were observed to be well tolerated in previous efficacy studies. The combinations DHA-PPQ and As-Pyr could potentially replace AL as first-line treatment in Burkina Faso if the results of these planned therapeutic efficacy studies continue to show a high rate of failures with AL. The herein study aims to assess the efficacy and safety of AL, DHA-PPQ and As-Pyr in the treatment of uncomplicated malaria in children in three health districts in Burkina Faso, namely the health districts of Banfora, Nanoro and de Gourcy. This study will provide PNLP and the Ministry of Health with additional data and evidence on the safety and efficacy of these treatments against malaria in Burkina Faso.
Primary objective The primary objective is to assess the clinical and parasitological efficacy of AL, DHA-PPQ and AS-Pyr in the treatment of uncomplicated P. falciparum malaria in children aged 6 months to 12 years, corrected by PCR on day 28 (AL) or 42 (DHA-PPQ & AS-Pyr).
Study settings The study will be conducted at the medical center (CMA of Niangoloko, the Clinical Research Unit of Nanoro (URCN) and the medical center with surgical antenna (CMA) of Gourcy.
Populations Febrile patients of both sexes aged between 6 months and 12 years with confirmed uncomplicated P. falciparum mono-infestation who wellcome for an outpatient visit to the health facilities.
Procedures It will be a multicenter, randomized, open-label, three-arm study involving three sites representing the three epidemiological facies of malaria in Burkina Faso. The three therapeutic combinations (AL, DHA-PPQ and As-Pyr) will be tested in different sites with different characteristics of transmission and resistance of malaria. Children with uncomplicated malaria who meet the criteria for inclusion in the study will be recruited and treated with the combination of AL or DHA-PPQ or As-Pyr. They will be monitored for 28 days for the AL group and 42 days for the DHA-PPQ and AS-Pyr arm. The follow-up will consist of scheduled control visits during which clinical examinations and laboratory tests will be carried out. A total of 1050 children will be enrolled in the study.
Main results
- The proportion of patients with early treatment failure, late clinical failure, late parasitological failure or adequate clinical and parasitological response.
- The frequency and nature of adverse events.
- The blood concentration of lumefantrine on day 7
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Adama Gansane, PharmD, PhD
- Phone Number: +22670233723
- Email: agansane@hotmail.com
Study Contact Backup
- Name: Siaka Debe, MD, MSc
- Phone Number: +22670938081
- Email: sk.debe@gmail.com
Study Locations
-
-
Kadiogo
-
Ouagadougou, Kadiogo, Burkina Faso, 2208
- Centre national de recherche et de formation sur le paludisme (CNRFP)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children of both sexes aged 6 months to 12 years inclusive;
- Microscopic confirmation of a monospecific infection by P. falciparum (Parasitaemia between 2000 - 200,000 / μl);
- Fever (uncorrected axillary or tympanic temperature ≥37.5 ° C or history of fever reported within the last 24 hours
- Hemoglobin level ≥ 5.0 g / dl
- Ability to take oral medication;
- Ability and willingness of parents to respect the protocol for the duration of the study and to respect the consultation schedule;
- Signature (or fingerprint (thumb) when parents / guardians are illiterate) of the consent form by the child's parents or guardians.
Exclusion Criteria:
- General danger signs in children under five (inability to drink or breastfeed, repeated vomiting (> 2 times in 24 hours), convulsions, unconsciousness, inability to sit or stand standing)
- Body weight less than 5 kg;
- Fever due to illnesses other than malaria (e.g. measles, acute lower respiratory infection, severe diarrheal illness with dehydration) or presence of other known chronic or serious underlying illnesses or any other condition (e.g. illness cardiac, renal or hepatic, HIV / AIDS) which in the judgment of the clinical investigator would place the subject at potential risk or interfere with the conduct of the study;
- Previous complete antimalarial treatment with an ACT within the last two weeks;
- History of hypersensitivity to any of the drugs tested
- Severe malnutrition (defined by a z score of weight for age less than -3 or other severe malnutrition sign).
- Known individual or family history of clinical disorders of prolongation of QT intervals or sudden death
- Previous participation in a malaria vaccine clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Artemether-lumefantrin (AL)
The tablets will be given orally according to patients' age and under supervision of study team as follows:
|
In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group.
Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided.
These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups.
The treatment to be administered will not be known until after the randomization process.
The drugs will be administered based on weight according to the instructions from the drug manufacturer.
AL will be administered with fatty food or milk according to the manufacturer's recommendations.
All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
Other Names:
|
EXPERIMENTAL: Dihydro-artemisinin-piperaquin (DHA-PPQ)
The tablets will be given orally according to patients' age and under supervision of study team as follows.
A single dose will be given on day 0, 1 and 2
|
In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group.
Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided.
These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups.
The treatment to be administered will not be known until after the randomization process.
The drugs will be administered based on weight according to the instructions from the drug manufacturer.
AL will be administered with fatty food or milk according to the manufacturer's recommendations.
All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
Other Names:
|
EXPERIMENTAL: Artesunate-Pyronaridin (As-Pyr)
The tablets will be given orally according to patients' age and under supervision of study team as follows.
A single dose will be given on day 0, 1 and 2
|
In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group.
Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided.
These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups.
The treatment to be administered will not be known until after the randomization process.
The drugs will be administered based on weight according to the instructions from the drug manufacturer.
AL will be administered with fatty food or milk according to the manufacturer's recommendations.
All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early treatment failure
Time Frame: 3 days
|
|
3 days
|
Late clinical failure
Time Frame: 24 days
|
|
24 days
|
Late parasitological failure
Time Frame: 21 days
|
Presence of parasitemia on any day between Day 7 and Day 28 and axillary temperature <37.5°C, without previously meeting any of the criteria of early treatment failure or late clinical failure.
|
21 days
|
Day 28 Adequate clinical and parasitological response PCR corrected
Time Frame: 28 days
|
Absence of parasitaemia by day 28 without previously meeting any of the criteria for ETF, LCF and LPF.
The number of cases of total treatment failure (TTF) will be computed as ETF+LCF+LPF
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events frequency and type
Time Frame: 28 days
|
Any unwanted sign/symptom occurred in patients after consentement signature
|
28 days
|
Pharmacocinetic of Lumefantrin
Time Frame: 7 days
|
Concentration of lumefantrin in blood at day 7 after IP administration
|
7 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Adama Gansane, PhD, Centre National de Recherche et de Formation sur le Paludisme
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Lumefantrine
- Artemether
- Artesunate
- Artemether, Lumefantrine Drug Combination
- Artenimol
- Pyronaridine
Other Study ID Numbers
- TET2020_001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Artemether-lumefantrine
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of Cape TownLondon School of Hygiene and Tropical MedicineCompletedHIV | MalariaSouth Africa
-
University of OxfordUniversity of KinshasaCompleted
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Completed
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Falciparum MalariaBurkina Faso, Benin, Congo, Nigeria, Togo
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitRecruitingHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health Sciences and other collaboratorsRecruitingMalaria,FalciparumUganda
-
Novartis PharmaceuticalsCenters for Disease Control and PreventionCompletedMalariaUnited States
-
NovartisCompletedMalaria | FalciparumBenin, Kenya, Mali, Mozambique, Tanzania
-
Centers for Disease Control and PreventionIfakara Health Research and Development CentreCompleted